Submit or Track your Manuscript LOG-IN

Clinical Effect of Apartinib Combined with Trastuzumab on Gastric Cancer with Ascites

Clinical Effect of Apartinib Combined with Trastuzumab on Gastric Cancer with Ascites

Xiaowei Zhang*

Medical Oncology, Baoding No.1 Central Hospital, Baoding, 071000, China

 
*      Corresponding author: zhangxiaowei202211@163.com

ABSTRACT

The objective of this study was to investigate the effect of two chemotherapeutic drugs, apatinib and trastuzumab, on gastric cancer with ascites. 225 patients with gastric cancer and ascites received by the Oncology Department and Gastrointestinal Department of the Central Hospital during October 2019-2021 were selected. They were subsequently assigned into apatinib group, trastuzumab group and combined treatment group. Compared with other treatment groups, the long-term and short-term survival rate of the apatinib treatment group was lower. The effective rate and adverse reaction rate of the three therapeutic drug intervention groups were significantly different. The correlation between survival time and CEA, CA125, CA19-9 tumor markers was 0.611, 0.603, 0.598, respectively, and all were significant. It was concluded that the combined treatment group of apatinib and trastuzumab can effectively intervene gastric cancer with ascites disease, reduce postoperative adverse reactions, promote cell apoptosis, especially the survival rate of long-term and short-term patients.

To share on other social networks, click on any share button. What are these?

Pakistan Journal of Zoology

August

Pakistan J. Zool., Vol. 56, Iss. 4, pp. 1501-2000

Featuring

Click here for more

Subscribe Today

Receive free updates on new articles, opportunities and benefits


Subscribe Unsubscribe